GAD65 Monoclonal Antibody (144), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA518053-Each-of-1 | In Stock | ₹ 55,714.00 |
PIMA518053 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 55,714.00
GST (18%): ₹ 10,028.52
Total Price: ₹ 65,742.52
Antigen
GAD65
Classification
Monoclonal
Concentration
1 mg/mL
Formulation
PBS with 0.09% sodium azide
Gene Accession No.
P48320, Q05329, Q05683
Gene Symbols
GAD2
Immunogen
Synthetic peptide: GSGFWSFGSEDGSGDSEN conjugated to KLH, corresponding to amino acids 4-22 of Human GAD65
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG1
Applications
Flow Cytometry, Immunoprecipitation, Western Blot, Western Blot
Clone
144
Conjugate
Unconjugated
Gene
GAD2
Gene Alias
6330404F12Rik; 65 kDa glutamic acid decarboxylase; GAD(65); GAD2; Gad-2; GAD65; GAD-65; Glutamate decarboxylase 2; Glutamate decarboxylase 2 (islet); glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa); glutamate decarboxylase 65 kDa isoform; Glutamate decarboxylase-2 (pancreas); glutamic acid decarboxylase 2; glutamic acid decarboxylase 65; MGC161605; MGC161607; RP11-420F12.2
Host Species
Mouse
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
14417, 24380, 2572
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Related Products
Description
- This target has a predicted molecular weight of 65 kDa
- GAD65 (glutamic acid decarboxylase-65) are present in autoimmune disorders such as insulin-dependent (type1) diabetes mellitus (IDDM), stiff man syndrome and polyendocrine autoimmune disease
- Auto-antibodies to GAD65 are present in 60-70% of individuals with newly diagnosed IDDM and thus are important markers for disease activity
- These auto-antibodies usually recognize conformation-dependent regions on GAD65 and rarely bind to the second isoform, GAD67
- Auto-antibodies to GAD67 are found in only 15% of recent-onset IDDM patients and most of this binding can be blocked with GAD65, suggesting shared epitopes between the two isoforms of GAD.